Foghorn Therapeutics INC Form 4 insider transactions

Foghorn Therapeutics' Chief Medical Officer, Alfonso Quintas Cardama, was granted stock options for 125,000 shares of common stock.

Foghorn Therapeutics' Chief Financial Officer, Kristian Humer, has been granted 120,000 stock options, vesting over four years.

Carlos Costa, Chief People Officer at Foghorn Therapeutics, was granted 115,000 stock options on January 22, 2025.

Anna Rivkin, Chief Business Officer of Foghorn Therapeutics Inc., reports the acquisition of stock options.

Foghorn Therapeutics CEO Adrian Gottschalk was granted options to purchase 400,000 shares of common stock on January 22, 2025.

Steven F. Bellon, Chief Scientific Officer of Foghorn Therapeutics, was granted stock options for 140,000 shares of common stock.

Michael LaCascia, Chief Legal Officer of Foghorn Therapeutics, was granted stock options for 126,000 shares of common stock.

Adam Koppel has resigned from the Board of Directors of Foghorn Therapeutics, effective December 29, 2024.

Carlos Costa, Chief People Officer of Foghorn Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Carlos Costa, Chief People Officer of Foghorn Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Carlos Costa, Chief People Officer of Foghorn Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Steven F. Bellon, Chief Scientific Officer of Foghorn Therapeutics, sold 20,000 shares of common stock at $9.50 per share on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Anna Rivkin, Chief Business Officer of Foghorn Therapeutics Inc., reports the acquisition of stock options.

Director Scott Biller of Foghorn Therapeutics Inc. reports the acquisition of 16,000 stock options on June 26, 2024.

Director Michael Mendelsohn acquired 16,000 stock options in Foghorn Therapeutics Inc. on June 26, 2024, at a price of $5.52 per share.

Director Ian F. Smith of Foghorn Therapeutics Inc. reports the acquisition of 16,000 stock options on June 26, 2024.

Director Thomas J. Lynch Jr. of Foghorn Therapeutics Inc. (FHTX) acquired 16,000 stock options on June 26, 2024, at a price of $5.52 per option.

Director Simba Gill acquired 16,000 stock options in Foghorn Therapeutics Inc. on June 26, 2024, according to a Form 4 filing.

Director Douglas G. Cole acquired 16,000 stock options in Foghorn Therapeutics Inc. on June 26, 2024, at an exercise price of $5.52.

Director B. Lynne Parshall acquired 16,000 stock options in Foghorn Therapeutics on June 26, 2024, according to a Form 4 filing.

Director Adam Koppel acquired 16,000 stock options in Foghorn Therapeutics Inc. on June 26, 2024, according to a Form 4 filing.

Fanny Cavalie, Chief Strategy/Bus Ops Officer of Foghorn Therapeutics, files a Form 4 indicating changes in beneficial ownership due to ceasing to be an officer of the company.

Flagship Pioneering Special Opportunities Fund II and Flagship Pioneering Fund VII acquired pre-funded warrants to purchase Foghorn Therapeutics common stock in a recent public offering.

Kristian Humer, CFO of Foghorn Therapeutics, reports the acquisition of stock options.

Fanny Cavalie, Chief Strategy/Bus Ops Officer at Foghorn Therapeutics, sold 11,000 shares of common stock at an average price of $6.5576 on March 11, 2024.